Adaptimmune Therapeutics PLC – (ADAP) Coverage Initiated by Analysts at Wells Fargo & Co

Wells Fargo & Co began coverage on shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) in a research report report published on Friday. The brokerage issued a market perform rating on the stock.

Separately, Zacks Investment Research raised shares of Adaptimmune Therapeutics PLC – from a sell rating to a hold rating in a report on Friday, March 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of $11.83.

Analyst Recommendations for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP)

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) traded down 3.58% during mid-day trading on Friday, hitting $4.58. The company had a trading volume of 191,485 shares. The stock’s market capitalization is $324.24 million. The stock has a 50 day moving average price of $4.34 and a 200-day moving average price of $5.01. Adaptimmune Therapeutics PLC – has a 1-year low of $3.76 and a 1-year high of $11.59.

var userip;Your IP Address: document.write(userip);

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vident Investment Advisory LLC increased its position in Adaptimmune Therapeutics PLC – by 165.0% in the fourth quarter. Vident Investment Advisory LLC now owns 193,869 shares of the company’s stock valued at $785,000 after buying an additional 120,724 shares during the period. Artal Group S.A. increased its position in Adaptimmune Therapeutics PLC – by 50.0% in the fourth quarter. Artal Group S.A. now owns 300,000 shares of the company’s stock valued at $1,215,000 after buying an additional 100,000 shares during the period. Renaissance Technologies LLC increased its position in Adaptimmune Therapeutics PLC – by 35.4% in the fourth quarter. Renaissance Technologies LLC now owns 445,100 shares of the company’s stock valued at $1,803,000 after buying an additional 116,400 shares during the period. Baker BROS. Advisors LP bought a new position in Adaptimmune Therapeutics PLC – during the third quarter valued at approximately $705,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Adaptimmune Therapeutics PLC – by 7.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 117,234 shares of the company’s stock valued at $826,000 after buying an additional 8,239 shares during the period. 43.67% of the stock is owned by institutional investors and hedge funds.

Adaptimmune Therapeutics PLC – Company Profile

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

5 Day Chart for NASDAQ:ADAP

Receive News & Ratings for Adaptimmune Therapeutics PLC - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC - and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Mattel CEO Promises Growth Following Sales Slump
Mattel CEO Promises Growth Following Sales Slump
Burberry Misses Estimates on Sales
Burberry Misses Estimates on Sales
Snapchat: CEO Did Not Label India as Being Poor
Snapchat: CEO Did Not Label India as Being Poor
Credit Suisse Slashes Bonuses by 40%
Credit Suisse Slashes Bonuses by 40%
Daily Mail to Pay Melania Trump $3 Million
Daily Mail to Pay Melania Trump $3 Million
New York Approves Free College Tuition
New York Approves Free College Tuition


© 2006-2017 Ticker Report. Google+.